Spotlight On... Sanofi, Regeneron rack up some cost-savings data for their PCSK9 contender Praluent; PhRMA goes on an image offensive; Biogen readies Lantus biosim in Japan; China needs to cut dependence on imported meds, drugmaker says; and more...

It's not the cardiovascular outcomes data doctors and payers are waiting for, but it's outcomes data nonetheless. Sanofi ($SNY) and Regeneron's ($REGN) PCSK9 contender Praluent helped patients with a severe form of high cholesterol cut back on pricey and cumbersome aphaeresis treatments, new late-stage study data show. More from FiercePharmaMarketing

@FiercePharma: Intersections snags $20M loan to support struggling Voyce health monitor for dogs. FierceAnimalHealth report | Follow @FiercePharma

@CarlyHFierce: ICYMI: With Cinqair nod, Teva squares off with GSK in severe asthma. Article | Follow @CarlyHFierce

> Steve Ubl, the new CEO of PhRMA, says the lobbying group will take an offensive, rather than defensive, approach to facing issues like concern over pharma price increases. Story

> India's Biocon has gotten approval from Japan for its biosimilar of Sanofi's ($SNY) Lantus, a step Managing Director Kiran Mazumdar-Shaw called a "credibility milestone" for the company. Story

> A Chinese drugmaker says the country needs more homegrown drugs to reduce its dependence on imports. Report

> A study says the risk of death goes way up for patients with Parkinson's disease who are treated with antipsychotic drugs. Blog Post

Medical Device News

@FierceMedDev: ICYMI: Philips shells out $35M to settle sleep apnea mask kickback charges with DOJ. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Medtronic to stop manufacturing some devices in Colorado in pursuit of $850M in promised synergies. Article | Follow @VarunSaxena2

@EmilyWFierce: Valeant's wounds bleed onto Ackman's Pershing Square with latest Senate probe. FiercePharma story | Follow @EmilyWFierce

> Ex med tech CEO faces jail time for bribing docs to promote skin-like wound dressing. Report

> Goldman Sachs invests $37M in Chinese TAVR player. Story

> Fed judge rules case against Bayer's Essure birth control device to move forward. Article

Biotech News

@FierceBiotech: UPDATED: FDA's internal review of Acadia's Parkinson's drug raises safety, benefit concerns. Article | Follow @FierceBiotech

@JohnCFierce: From the weekend bureau: Forum faces the end o' the road. Story | Follow @JohnCFierce

> Alder rockets up as promising migraine data heats up a frenzied race for CGRP drug approval. Story

> Under pressure, XenoPort sells U.S. rights of failed psoriasis pill to Dr. Reddy's. Article

> Aduro offers $7.5M to fuel UC Berkeley's immunotherapy research effort. More

Animal Health News

> Akorn emerges from audit with better-than-expected 2015 results. Item

> Neogen plunges on Q3 miss as CEO seeks global growth for gene-testing services. Article

> Genes in canine bone tumors predict drug response: Report. More

> Intersections snags $20M loan to support struggling Voyce health monitor for dogs. News

> Roslin turns to business with new animal health venture. Report

Biotech IT News

> Lundbeck upgrades ArisGlobal regulatory and safety IT system. Item

> 23andMe tech brings genetic data to Apple ResearchKit studies. More

> Overturning bioinformatic predictions, Venter creates minimal synthetic cell with 473 genes. Story

> Sony-backed M3, Endeavour Vision unveil digital health investment funds. Article

> Microsoft co-founder commits $100M to early-stage research at intersection of IT and biology. Report

Pharma Marketing News

> Looking for a respiratory edge, Boehringer teams with Propeller to test 'smart inhaler' for adherence. Article

> Apple's CareKit opens new door for pharma to develop apps, but will it walk through? More

> Could J&J get an image boost from new health-oriented research? Experts say yes. Story

> Novartis kickbacks blows up as feds demand info on 80,000 doc events. Item

And Finally... During a trip to Cuba, Pfizer's Dave Verbraska, VP of worldwide public affairs, found state-run pharmacies, domestically produced generic drugs and few imports. Blog Post